We have outlined the management of dyslipidemia for stroke prevention from the perspective of J-STARS. The current situation wherein the results of many large-scale clinical trials conducted in Western countries have been adapted for our daily medical treatment is not satisfactory. This is because many differences in medical situations, including stroke incidence rates and doses of medicine for clinical use, exist between Asians and Caucasians. Therefore, it is possible that adoption of clinical study results conducted in Caucasians for Asians is insubstantial. J-STARS results showed that low dose mild statin use may reduce atherothrombotic stroke incidence in patients with non-cardioembolic stroke. Currently, the desirable LDL-cholesterol level for preventing ischemic stroke in Asians is unclear. The results of further examinations are awaited regarding this aspect.